Financial news for GNCA dated on 2020-05-29: Genocea Presents Updated Long-Term Safety, Immunogenicity And Durability Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A At Virtual ASCO 2020

Financial news for GNCA dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant

Financial news for GNCA dated on 2020-05-24: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for GNCA dated on 2020-05-19: Genocea Announces Material Transfer And License Option Agreement With Shionogi For Proprietary GEN-003 HSV-2 Antigens; Shionogi To Pay \$2M For Exclusive Option

Financial news for GNCA dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for GNCA dated on 2020-05-14: 32 Stocks Moving in Thursday's Pre-Market Session

Financial news for GNCA dated on 2020-05-13: Genocea Highlights Will Present Long-Term Follow-Up Data From GEN-009 Vaccine At ASCO

Financial news for GNCA dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for GNCA dated on 2020-05-13: 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for GNCA dated on 2020-05-13: 30 Stocks Moving in Wednesday's Pre-Market Session

Financial news for GNCA dated on 2020-05-12: UPDATE: Genocea Sees GEN-011 Investigational New Drug Filing By End Of Q2, Sees Prelim. Clinical Data H1'21

Financial news for GNCA dated on 2020-05-12: Genocea Biosciences Highlights Introduction Of GEN-011 To Improve On Current Limitations Of TIL Therapy

Financial news for GNCA dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for GNCA dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for GNCA dated on 2020-05-07: Genocea Biosciences Shares Spike To Session High On Volume As Traders Circulate World Intellectual Property Organization PatentScope Doc For 'Methods and compositions for identifying tumor antigens of human lymphocytes'

Financial news for GNCA dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for GNCA dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for GNCA dated on 2020-03-09: 100 Biggest Movers From Friday

Financial news for GNCA dated on 2020-03-06: How Not To Day Trade

Financial news for GNCA dated on 2020-03-04: UPDATE: Hearing Genocea Granted European Patent EP2665490 For 'Vaccines And Compositions Against Streptococcus Pneumoniae'

Financial news for GNCA dated on 2020-03-04: Genocea Biosciences Shares Spike To Session High, Up 9.5%, As Hearing Traders Circulate Word Of European Patent

Financial news for GNCA dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for GNCA dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for GNCA dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for GNCA dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for GNCA dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for GNCA dated on 2020-02-25: Genocea Biosciences Shares Spike To Session High Of Volume As Traders Circulate Chatter Of Patent for Possible Coronavirus Candidate 'In some embodiments, members of a library include polynucleotides that encode polypeptides from a virus'

Financial news for GNCA dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for GNCA dated on 2020-02-13: Genocea Biosciences Q4 EPS \$(0.34) Beats \$(0.39) Estimate

Financial news for GNCA dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for GNCA dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for GNCA dated on 2020-01-17: 76 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-12-31: 11 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for GNCA dated on 2019-11-15: Benzinga's Top Upgrades, Downgrades For November 15, 2019

Financial news for GNCA dated on 2019-11-15: SVB Leerink Initiates Coverage On Genocea Biosciences with Outperform Rating

Financial news for GNCA dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for GNCA dated on 2019-11-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for GNCA dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for GNCA dated on 2019-11-05: Genocea Presents Preclinical Research On Inhibitory Neoantigens Showing They 'Stifle Protective Anti-Tumor Immune Responses' At Society For Immunotherapy Of Cancer (SITC)

Financial news for GNCA dated on 2019-10-24: Genocea Biosciences Filing Shows Registration For \$30M Common Stock Offering

Financial news for GNCA dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for GNCA dated on 2019-10-24: Genocea Biosciences Q3 EPS (0.28) Beats (0.46) Estimate

Financial news for GNCA dated on 2019-09-30: Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More

Financial news for GNCA dated on 2019-09-27: Genocea Biosciences Highlights Poster Presentation at ESMO Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

Financial news for GNCA dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for GNCA dated on 2019-08-24: 10 Biopharmaceutical Companies Trying To Cure Cancer

Financial news for GNCA dated on 2019-07-25: Genocea Biosciences Q2 EPS (0.42) Beats (0.66) Estimate

Financial news for GNCA dated on 2019-07-25: Genocea Biosciences Says it Expects to Have Enough Cash to Operate Through Q1 2021

Financial news for GNCA dated on 2019-07-08: Stifel Reinstates Buy on Genocea Biosciences

Financial news for GNCA dated on 2019-06-27: 54 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-06-26: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GNCA dated on 2019-06-26: Genocea Biosciences Shares Spike Higher On Uptick In Volume Amid Filing Showing GlaxoSmithKline Purchased $\sim 1.86 M$ Shares Of Co.'s Common Stock

Financial news for GNCA dated on 2019-06-21: 54 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-06-20: Genocea shares are trading lower after the company priced a 10.5 million share common stock offering at \$3.50 per share.

Financial news for GNCA dated on 2019-06-20: 35 Stocks Moving In Thursday's Mid-Day Session

Financial news for GNCA dated on 2019-06-20: Mid-Morning Market Update: Markets Open Higher; Kroger Posts Upbeat Sales

Financial news for GNCA dated on 2019-06-20: 55 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-06-20: Genocea Prices 10.5M Share Public Offering of Common Stock @\$3.50/Share

Financial news for GNCA dated on 2019-06-19: Genocea Biosciences shares are trading lower after the company reported a 10 million shares common stock offering.

Financial news for GNCA dated on 2019-06-19: Mid-Afternoon Market Update: Federal Reserve Leaves Rates Unchanged; Foresight Shares Spike Higher

Financial news for GNCA dated on 2019-06-19: Mid-Day Market Update: Melinta Therapeutics Gains After FDA Accepts sNDA For Bacterial Pneumonia Drug; Sesen Bio Shares Drop

Financial news for GNCA dated on 2019-06-19: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GNCA dated on 2019-06-19: 36 Stocks Moving In Wednesday's Pre-Market Session

Financial news for GNCA dated on 2019-06-19: The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Financial news for GNCA dated on 2019-06-19: A Peek Into The Markets: US Stock Futures Flat; All Eyes On Fed Decision

Financial news for GNCA dated on 2019-06-19: 8 Stocks To Watch For June 19, 2019

Financial news for GNCA dated on 2019-06-18: Genocea Biosciences shares are trading lower after the company reported a 10 million shares common stock offering.

Financial news for GNCA dated on 2019-06-18: Genocea Reports 10M Share Common Stock Offering

Financial news for GNCA dated on 2019-06-17: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for GNCA dated on 2019-06-10: 60 Biggest Movers From Friday

Financial news for GNCA dated on 2019-06-07: 3 Foolproof Strategies To Minimize Risk

Financial news for GNCA dated on 2019-06-07: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for GNCA dated on 2019-06-06: 66 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-06-05: Genocea Biosciences Shares Resume Trade, Spike Sharply Higher, Now Up 10.5% For Session

Financial news for GNCA dated on 2019-06-05: 54 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-06-04: A Look At Benzinga Pro's Most-Searched Tickers For June 4, 2019

Financial news for GNCA dated on 2019-06-04: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for GNCA dated on 2019-06-04: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., June 4, 2019

Financial news for GNCA dated on 2019-06-04: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GNCA dated on 2019-06-04: 66 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-06-03: Mid-Afternoon Market Update: NASDAQ Down 1.5%; Genocea Biosciences Shares Spike Higher

Financial news for GNCA dated on 2019-06-03: A Look At Benzinga Pro's Most-Searched Tickers For June 3, 2019

Financial news for GNCA dated on 2019-06-03: Genocea Biosciences Rallies 50% On ASCO Presentation

Financial news for GNCA dated on 2019-06-03: 51 Stocks Moving In Monday's Mid-Day Session

Financial news for GNCA dated on 2019-06-03: Mid-Day Market Update: El Paso Electric Rises On Acquisition News; DelMar Pharmaceuticals Shares Plummet

Financial news for GNCA dated on 2019-06-03: Mid-Morning Market Update: Markets Mixed; Infineon To Buy Cypress Semiconductor For \$10B

Financial news for GNCA dated on 2019-06-03: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., June 3, 2019

Financial news for GNCA dated on 2019-06-03: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for GNCA dated on 2019-06-03: Genocea Biosciences shares are trading higher after the company presented results from its ongoing Phase 1/2a trial for GEN-009, the company's lead neoantigen vaccine candidate, at ASCO 2019.

Financial news for GNCA dated on 2019-06-03: Genocea Biosciences Announce Clinical Results From its Phase 1/2a Trial for GEN-009

Financial news for GNCA dated on 2019-06-03: 64 Biggest Movers From Friday

Financial news for GNCA dated on 2019-05-31: Mid-Afternoon Market Update: Dow Falls Over 300 Points; Williams-Sonoma Shares Climb On Upbeat Earnings

Financial news for GNCA dated on 2019-05-31: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for GNCA dated on 2019-05-31: Mid-Day Market Update: Crude Oil Down 2.9%; Stellar Biotechnologies Shares Spike Higher

Financial news for GNCA dated on 2019-05-31: Low-Float Du Jour: Genocea Biosciences

Financial news for GNCA dated on 2019-05-31: Mid-Morning Market Update: Markets Open Lower; Big Lots Earnings Top Expectations

Financial news for GNCA dated on 2019-05-31: Genocea Biosciences Shares Resume Trade, Up 57.3%

Financial news for GNCA dated on 2019-05-31: Genocea Biosciences Shares Halted On Second Circuit Breaker, Up 57.3%

Financial news for GNCA dated on 2019-05-31: Genocea Biosciences Shares Resume Trade, Continue Higher, Now Up 44.5%

Financial news for GNCA dated on 2019-05-31: Genocea Biosciences Shares Halted On Circuit Breaker

Financial news for GNCA dated on 2019-05-31: Genocea's GEN-009 Clinical Results Presentation Selected By ASCO's Journal Of Clinical Oncology As A Top 10 Featured Immuno-oncology Abstract

Financial news for GNCA dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for GNCA dated on 2019-05-21: Genocea Biosciences 8-K Shows News Of 1-For-8 Reverse Stock Split Effective May 22, 2019

Financial news for GNCA dated on 2019-05-16: Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward

Financial news for GNCA dated on 2019-05-16: Genocea Reports Interim Immunogenicity

Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial: 'Post-vaccination immune responses detected to 93% of vaccine neoantigens in first three patients analyzed'

Financial news for GNCA dated on 2019-04-30: Genocea Biosciences Q1 EPS \$(0.15) Misses \$(0.09) Estimate

Financial news for GNCA dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for GNCA dated on 2019-04-03: Genocea Biosciences shares are trading higher after the company presented data supporting the utility of its ATLAS platform at the AACR 2019 event.

Financial news for GNCA dated on 2019-02-28: Genocea Biosciences shares down sharply, well below the \$1 level, following slightly worse-than-expected Q4 results and news of a new CFO, Diantha Duvall

Financial news for GNCA dated on 2019-02-28: Genocea Biosciences Q4 EPS (0.13) Misses (0.12) Estimate

Financial news for GNCA dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for GNCA dated on 2019-01-03: 66 Biggest Movers From Yesterday

Financial news for GNCA dated on 2019-01-02: 45 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GNCA dated on 2019-01-02: Genocea Biosciences shares are trading higher after the company announced it dosed its first patients and completed enrollment in Part A of Phase 1/2a in the clinical trial for the neoantigen vaccine candidate, GEN-009.

Financial news for GNCA dated on 2019-01-02: Genocea Biosciences Doses First Patients And Completes Enrollment In Part A Of Phase 1/2a Clinical Trial For Neoantigen Vaccine Candidate GEN-009

Financial news for GNCA dated on 2018-12-28: The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Financial news for GNCA dated on 2018-12-27: The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede

Financial news for GNCA dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for GNCA dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for GNCA dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for GNCA dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for GNCA dated on 2018-11-01: Genocea Biosciences Q3 EPS \$(0.09) Beats \$(0.11) Estimate

Financial news for GNCA dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for GNCA dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for GNCA dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for GNCA dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for GNCA dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for GNCA dated on 2018-09-13: Stocks Which Set New 52-Week Low Yesterday, September 12th

Financial news for GNCA dated on 2018-09-13: The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For

Financial news for GNCA dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for GNCA dated on 2018-09-12: The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Financial news for GNCA dated on 2018-08-02: Stocks Which Set New 52-Week Low Yesterday, August 1st

Financial news for GNCA dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for GNCA dated on 2018-08-02: Genocea Biosciences Q2 EPS (0.05) Beats (0.13) Estimate

Financial news for GNCA dated on 2018-08-01: Stocks Which Set New 52-Week Low Yesterday, July 31

Financial news for GNCA dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for GNCA dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for GNCA dated on 2018-07-26: Stocks Which Set New 52-Week Low Yesterday, July 25th

Financial news for GNCA dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for GNCA dated on 2018-07-25: Stocks Which Set New 52-Week Lows Yesterday, July 24th:

Financial news for GNCA dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for GNCA dated on 2018-07-24: Stocks Which Set New 52-Week Lows Yesterday:

Financial news for GNCA dated on 2018-07-24: Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering

Financial news for GNCA dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

Financial news for GNCA dated on 2018-07-17: Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

Financial news for GNCA dated on 2018-05-21: Genocea Biosciences S-3 Shows Registration For \$200M Mixed Securities Shelf Offering

Financial news for GNCA dated on 2018-05-10: Genocea Biosciences Q1 EPS \$(0.21) Misses \$(0.15) Estimate

Financial news for GNCA dated on 2018-04-30: Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009

Financial news for GNCA dated on 2018-04-18: Genocea Biosciences To Offer Data On ATLAS Platform At AACR: Showed In Silico Methods Missed Most Empirically Confirmed Neoantigens

Financial news for GNCA dated on 2018-03-09: 56 Biggest Movers From Yesterday

Financial news for GNCA dated on 2018-03-08: HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies

Financial news for GNCA dated on 2018-03-08: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for GNCA dated on 2018-03-08: Benzinga's Top Upgrades, Downgrades For March 8, 2018

Financial news for GNCA dated on 2018-03-08: H.C. Wainwright Initiates Coverage On Genocea Biosciences with Buy Rating, Announces \$5.00 Price Target

Financial news for GNCA dated on 2018-03-07: Benzinga Pro's Top 10 Most-Searched Tickers On Wed., Mar. 7

Financial news for GNCA dated on 2018-03-06: Benzinga Pro's Top 10 Most-Searched Tickers On Tues., Mar. 6

Financial news for GNCA dated on 2018-03-06: Genocea Biosciences Shares Up 15.2% After Cantor Fitzgerald Earlier Initiated Stock At Overweight

Financial news for GNCA dated on 2018-03-06: Cantor Fitzgerald Initiates Coverage On Genocea Biosciences with Overweight Rating, Announces \$5.00 Price Target

Financial news for GNCA dated on 2018-02-15: Genocea Biosciences Reports Q4 Net Loss \$10.7M vs Loss Of \$16M In Same Qtr. Last Year

Financial news for GNCA dated on 2018-02-12: Benzinga's Top Upgrades, Downgrades For February 12, 2018

Financial news for GNCA dated on 2018-02-12: Baird Initiates Coverage On Genocea Biosciences with Outperform Rating, Announces \$3.00 Price Target

Financial news for GNCA dated on 2018-02-06: Needham Upgrades Genocea Biosciences to Buy

Financial news for GNCA dated on 2018-01-26: Genocea Biosciences 13G Filing From Vivo Opportunity Shows New 9.99% Stake

Financial news for GNCA dated on 2018-01-26: New Enterprise Associates Reports 39.7% Stake In Genocea Biosciences Inc As Of Jan 17 -13D

Financial news for GNCA dated on 2018-01-17: Genocea Biosciences Prices Offering Of $\sim 53.4 \text{M}$ Common Shares Accompanying Class A Warrants To Buy Up To $\sim 26.68 \text{M}$ Shares At \$1/Share For Gross Proceeds \$53.4M

Financial news for GNCA dated on 2018-01-16: Genocea Biosciences Reports Offering Of Common Stock, Class A Warrants, Series A Convertible Preferred Stock

Financial news for GNCA dated on 2017-11-07: Genocea Offers New Results For ATLAS Antigen ID Platform: 'ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types'

Financial news for GNCA dated on 2017-11-02: Genocia Reports Q3 EPS (0.59) vs. (0.53) Est.

Financial news for GNCA dated on 2017-09-26: Mid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares Plunge

Financial news for GNCA dated on 2017-09-26: What The GEN-003 News Means For Genocea

Financial news for GNCA dated on 2017-09-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for GNCA dated on 2017-09-26: Mid-Day Market Update: Crude Oil Down Over 1%; Moleculin Biotech Shares Spike Higher

Financial news for GNCA dated on 2017-09-26: Mid-Morning Market Update: Markets Open Higher; FactSet Research Profit Beats Views

Financial news for GNCA dated on 2017-09-26: Genocea Shares Down $\sim\!63\%$ Just Before Market Open

Financial news for GNCA dated on 2017-09-26: Street Abandons Genocea On Strategic Shift, CEO Says Oncology Focus Wasn't Sudden

Financial news for GNCA dated on 2017-09-26: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GNCA dated on 2017-09-26: Stifel Nicolaus Downgrades Genocea Biosciences to Hold

Financial news for GNCA dated on 2017-09-25: Genocea CEO Clark On Reviewing Of Strategic Alternatives For GEN-003, Tells Benzinga, '...we seek the right partner to move the program forward.'

Financial news for GNCA dated on 2017-09-25: Genocea CEO Clark On GEN-003 Decision, Tells Benzinga, 'The significant financial resources required to advance GEN-003 into a large and long Phase 3 program are beyond Genocea alone.'

Financial news for GNCA dated on 2017-09-25: Genocea CEO Chip Clark Elaborates On Decision To Shift Toward Immuno-oncology, Highlights To Benzinga, '...the great

potential we see for our ATLAS platform to be superior to others' approaches for neoantigen selection'

Financial news for GNCA dated on 2017-09-25: Genocea Shares Fall $\sim\!35\%$ Shortly After Resumption

Financial news for GNCA dated on 2017-09-25: Genocea Shares Open For Trade Following Halt; Not Yet Seeing Any Price Action

Financial news for GNCA dated on 2017-09-25: Genocea Shares To Resume Trade At 5 p.m. EDT

Financial news for GNCA dated on 2017-09-25: UPDATE: Genocea Sees Existing Cash, Cash Equivalents Sufficient To Support Operating, Capital Expense Requirements Into Middle Of '18

Financial news for GNCA dated on 2017-09-25: UPDATE: Genocea Sees Annualized Savings Of \sim \$6.5M In Personnel-Related Costs, Sees 1-Time Severance Charge Of \sim \$1.1M In Q3'17

Financial news for GNCA dated on 2017-09-25: UPDATE: Genocea Says Is Ceasing GEN-003 Spending, Activities, Is Reducing Workforce By $\sim 40\%$

Financial news for GNCA dated on 2017-09-25: UPDATE: Genocea Says 'plans to initiate a Phase 1 clinical trial for GEN-009 in a range of tumor types in 1H'18 and expects to report initial immunogenicity data in the 1H'19'

Financial news for GNCA dated on 2017-09-25: UPDATE: Genocea Reports Corporate Restructuring

Financial news for GNCA dated on 2017-09-25: UPDATE: Genocea Announces Will Explore Strategic Alternatives For GEN-003

Financial news for GNCA dated on 2017-09-25: Genocea Reports Strategic Shift To Immuno-oncology, Development Of Neoantigen Cancer Vaccines

Financial news for GNCA dated on 2017-09-25: Genocea Shares Halted News Pending

Financial news for GNCA dated on 2017-08-09: Genocea Biosciences Reports Q2 EPS \$(0.54) vs \$(0.47) Est.

Financial news for GNCA dated on 2017-07-25: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GNCA dated on 2017-07-24: Genocea Shares Spike ~\$0.30 Higher Over Last Min. As Traders Circulating Report Of Cowen Research Note Highlighting Belief GEN-003 Has Greater Than \$700M Peak Sales Potential

Financial news for GNCA dated on 2017-07-24: Hearing Needham Upgrades Genocea From Hold To Buy

Financial news for GNCA dated on 2017-07-24: 18 Biggest Mid-Day Gainers For Monday

Financial news for GNCA dated on 2017-07-24: Genocea BeioSciences Shares Up 11.7% Pre-Market On Report Of 'Positive' Phase 2b Data for GEN-003

Financial news for GNCA dated on 2017-07-24: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for GNCA dated on 2017-07-24: Genocea Reports 'Positive' Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes

Financial news for GNCA dated on 2017-05-04: Genocea Biosciences Q1 EPS \$(0.48) vs \$(0.54) Est, No Sales

Financial news for GNCA dated on 2017-03-08: Hearing Unconfirmed Market Chatter of \$12-\$15 Bid for Genocea

Financial news for GNCA dated on 2017-02-17: Needham Downgrades Genocea Biosciences To Hold

Financial news for GNCA dated on 2017-02-16: Genocea Biosciences Reports Q4 Net Loss $$16M \times 1000 = 1000$ Vs Net Loss $$10.3M \times 1000 = 1000$ Vs Net Loss $$10.3M \times 1000 = 1000$

Financial news for GNCA dated on 2017-01-05: 15 Biggest Mid-Day Gainers For Thursday

Financial news for GNCA dated on 2017-01-05: Genocea Biosciences Higher Off Positive Clinical Data, Favorable Analyst Comments

Financial news for GNCA dated on 2017-01-05: Cowen Out Positive On Genocea

Biosciences, Says Co. Is Significantly Undervalued

Financial news for GNCA dated on 2017-01-05: Genocea Shares Bounce from Session Lows as Traders Passing Around Word of Increased Price Target from \$13 to \$17 at Piper Jaffray

Financial news for GNCA dated on 2017-01-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for GNCA dated on 2017-01-05: Genocea +21% Premarket @\$5.49 After Announcing Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial

Financial news for GNCA dated on 2017-01-05: Genocea Announces 'Positive' 6-Month Results from GEN-003 Phase 2b Clinical Trial

Financial news for GNCA dated on 2016-11-11: Genocea Reports ATLAS 'discovers neoantigens, through functional T cell responses, which were not identified by predictive algorithms'

Financial news for GNCA dated on 2016-11-03: Genocea Biosciences Reports Q3 EPS \$(0.45) vs. Est. \$(0.44)

Financial news for GNCA dated on 2016-11-03: Genocea Q3 EPS \$(0.45) vs \$(0.44) Est, No Revenue

Financial news for GNCA dated on 2016-10-28: 20 Biggest Mid-Day Gainers For Friday

Financial news for GNCA dated on 2016-10-28: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for GNCA dated on 2016-10-28: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003; Says Data Provide Strong Evidence of Clear, Robust T, B Cell Immune Responses

Financial news for GNCA dated on 2016-10-26: 15 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for GNCA dated on 2016-09-30: 18 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for GNCA dated on 2016-09-29: 12 Biggest Mid-Day Losers For Thursday

Financial news for GNCA dated on 2016-09-29: UPADTE: Needham Says 'We continue to view GEN-003 favorably', Expects Moderate Improvements Over Current HSV2 Standard Of Care In Patients W/ More Active Disease

Financial news for GNCA dated on 2016-09-29: Needham Positive On Genocea, Reiterating Buy, PT \$15

Financial news for GNCA dated on 2016-09-29: PiperJaffray Maintains Overweight on Genocea Biosciences, Raises PT to \$12.00, Expects GEN-003 Approval In 20200 And US Launch In 2021 W/ Sales Exceeding \$1B By 2025

Financial news for GNCA dated on 2016-09-29: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for GNCA dated on 2016-09-29: Genocea Shares to Resume Trade at 8 a.m.

Financial news for GNCA dated on 2016-09-29: Genocea Reports Phase 2b Trial of GEN-003 for Genital Herpes Met Primary Endpoint, Dose is Confirmed for Subsequent Trials

Financial news for GNCA dated on 2016-09-29: Genecea Shares Halted News Pending

Financial news for GNCA dated on 2016-09-26: Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genocea Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals

Financial news for GNCA dated on 2016-08-04: Genocea Reports Q2 EPS \$(0.39) vs. \$(0.44)

Financial news for GNCA dated on 2016-05-05: Genocea Reports Q1 Net Loss \$9.8M vs \$12.1M in Same Qtr. Last Year

Financial news for GNCA dated on 2016-04-01: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for GNCA dated on 2016-04-01: Genocea Shares Spike to Premarket High of \$7.94

Financial news for GNCA dated on 2016-04-01: Must Watch Stocks for Today

Financial news for GNCA dated on 2016-03-31: 10 Stocks Moving In Today's After-Hours Session

Financial news for GNCA dated on 2016-03-31: Adam Feuerstein Tweets:@IraBidermanDDS The GEN-003 vs placebo lesion reduction data disclosed by \$GNCA today (slides 9 & 10) look terrible. No difference.

Financial news for GNCA dated on 2016-03-31: Cowen Cautions the 'Market Exclusivity of Genocea's Vaccines is Largely Dependent on their Patents, Which Could be Subject to Challenge'

Financial news for GNCA dated on 2016-03-31: Genocea Shares Moving Higher; Cowen Reiterates Outperform, \$40 PT

Financial news for GNCA dated on 2016-03-31: Genocea Biosciences Spikes 30% After Positive Data From Phase 2 Trial

Financial news for GNCA dated on 2016-03-31: Genocea Biosciences Reports GEN-003 Showed Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post Dosing

Financial news for GNCA dated on 2016-02-11: Genocea Reports Q4 EPS \$(0.37) vs. Est. \$(0.40)

Financial news for GNCA dated on 2016-01-29: Genocea Starts Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003; Top-Line Data Expected Mid-2016

Financial news for GNCA dated on 2015-12-17: Benzinga's Top Initiations

Financial news for GNCA dated on 2015-12-17: UBS Initiates Coverage on Genocea Biosciences at Buy, Announces \$15.00 PT

Financial news for GNCA dated on 2015-11-04: Genocea Presents Positive Findings from ATLASTM Immuno-Oncology Research Collaboration at 2015 SITC Annual Meeting

Financial news for GNCA dated on 2015-10-19: Mid-Afternoon Market Update: Genocea Biosciences Declines Following Announcement of Suspension of Development of GEN-004; PMC-Sierra Shares Surge

Financial news for GNCA dated on 2015-10-19: Mid-Day Market Update: Weight Watchers Jumps On Oprah Stake; Great Lakes Dredge & Dock Shares Drop

Financial news for GNCA dated on 2015-10-19: Stocks Hitting 52-Week Lows

Financial news for GNCA dated on 2015-10-19: Mid-Morning Market Update: Markets Mixed; Morgan Stanley Profit Misses Views

Financial news for GNCA dated on 2015-10-19: Morning Market Losers

Financial news for GNCA dated on 2015-10-19: Benzinga's Top #PreMarket Losers

Financial news for GNCA dated on 2015-10-19: Genocea Biosciences -34% Premarket Following Announcement of Suspension of Development of GEN-004

Financial news for GNCA dated on 2015-10-19: Genocea Biosciences to Resume Trading @7:30 AM ET

Financial news for GNCA dated on 2015-10-19: UPDATE: Genocea Suspends Development Pending Further Review of Data and Potential Paths Forward

Financial news for GNCA dated on 2015-10-19: UPDATE: Genocea Biosciences Says Consistent Reductions vs Placebo in Rate, Density of Colonization; Not Statistically Significant

Financial news for GNCA dated on 2015-10-19: Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004

Financial news for GNCA dated on 2015-10-19: Genocea Biosciences Halted; Pending News

Financial news for GNCA dated on 2015-10-07: Genocea Biosiences Says Phase 2 Study Results Positive For Multiple Endpoints

Financial news for GNCA dated on 2015-08-06: Genocea Reports Q2 EPS \$(0.43) vs. Est. \$(0.51)

Financial news for GNCA dated on 2015-07-30: Genocea Biosciences Prices \$50M Offering At \$13/Share

Financial news for GNCA dated on 2015-05-20: Benzinga's Volume Movers

Financial news for GNCA dated on 2015-05-20: Morning Market Gainers

Financial news for GNCA dated on 2015-05-20: Genocea Reports Top-Line Phase 2 Data for GEN-003: Showed Highlty Statistically Significant 55% Reduction in Viral Shedding Rate with Best Dose

Financial news for GNCA dated on 2015-05-08: Genocea Biosciences Files \$250M Mixed Shelf

Financial news for GNCA dated on 2015-04-22: Genocea Completes Enrollment in Phase 2a Human Challenge Study of GEN-004 for the Prevention of Infection by Pneumococcus

Financial news for GNCA dated on 2015-04-22: Genocea Finishes Enrollment in Phase 2a Human Challenge Study of GEN-004 for the Prevention of Infection by Pneumococcus

Financial news for GNCA dated on 2015-04-21: Benzinga's Top Initiations

Financial news for GNCA dated on 2015-04-21: FBR Capital Initiates Genocea Biosciences With Outperform

Financial news for GNCA dated on 2015-04-21: FBR Capital Initiates Coverage on Genocea Biosciences at Outperform, Announces \$20.00 PT\$

Financial news for GNCA dated on 2015-03-18: Piper Jaffray Initiates Coverage on Genocea Biosciences at Overweight, Announces \$14.00 PT

Financial news for GNCA dated on 2015-03-17: Genocea Biosciences Director Hoffman Buys 700,000 Shares @\$8.25/Share -Form 4

Financial news for GNCA dated on 2015-03-12: Genocea Biosciences Prices \$45M Offering At \$8.25/Share

Financial news for GNCA dated on 2015-02-12: Genocea Reports Fourth Quarter Q4 EPS \$(0.66)

Financial news for GNCA dated on 2015-01-07: Genocea Biosciens Says It Expects Topline Phase 2 Data in Late Q2

Financial news for GNCA dated on 2014-12-15: Genoca Appoints Eric Hoffman As Chief Business Officer

Financial news for GNCA dated on 2014-11-21: Genocea Biosciences Enters Loan Agreement With Hercules Technology Growth Capital For Up To \$27M

Financial news for GNCA dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for GNCA dated on 2014-11-07: UPDATE: Stifel Reiterates On Genocea Biosciences On Attractive Risk/Reward

Financial news for GNCA dated on 2014-11-07: Stifel Nicolaus Maintains Buy on Genocea, Lowers PT to \$24.00

Financial news for GNCA dated on 2014-11-06: Genocea Reports Q3 EPS of \$(0.53) vs \$(0.51) Est

Financial news for GNCA dated on 2014-10-08: Genocea Reports Closing of Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek

Financial news for GNCA dated on 2014-09-23: Genocea Announces \$1.2M Grant

Financial news for GNCA dated on 2014-09-11: Genocea Announces Commencement of Phase 2a Trial for GEN-004, Says Expects to Enroll ~90 Patients

Financial news for GNCA dated on 2014-08-06: Genocea Reports Q2 EPS of \$(0.41) vs \$(0.45) Est

Financial news for GNCA dated on 2014-07-21: Genocea Announces Start of Phase 2 Dosing

Financial news for GNCA dated on 2014-07-16: Genocea Biosciences Announces Has Elected Not to Pursue Offering

Financial news for GNCA dated on 2014-07-14: Amended S-1 Filing from Genocea

Biosciences Shows Will Sell 3.4M Shares Through Offering

Financial news for GNCA dated on 2014-07-14: Genocea Biosciences Reports Commencement of Offering of 3.4M Shares

Financial news for GNCA dated on 2014-07-01: Genocea Announces Positive Top Line Results for Phase 1/2a Trail

Financial news for GNCA dated on 2014-06-23: Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004

Financial news for GNCA dated on 2014-04-07: Genocea Appoints Jonathan Poole as CFO

Financial news for GNCA dated on 2014-03-24: UPDATE: Genocea Says Patients Saw 72% Reduction in Lesion Days After Six Months, Expecting to Announce 12-Month Data in Mid 2014

Financial news for GNCA dated on 2014-03-24: Genocea's Therapeutic Vaccine For Herpes Simplex-2 Infection Shows Highly Significant Reductions In Clinical Symptoms at 6 Months

Financial news for GNCA dated on 2014-03-07: Mid-Day Gainers Mar. 7, 2014: SKUL, SMSI, DLIA, BIG, CVM, KFY, GTAT

Financial news for GNCA dated on 2014-03-05: Needham Initiates Coverage on Genocea at Buy, Announces \$22.00 PT

Financial news for GNCA dated on 2014-03-03: Stifel Nicolaus Initiates Coverage on Genocea at Buy, Announces \$25.00 PT

Financial news for GNCA dated on 2014-03-03: Citigroup Initiates Coverage on Genocea at Buy, Announces $$25.00 \ PT$

Financial news for GNCA dated on 2014-02-05: Shares of Genocea Biosciences Open at \$11.70/Share After Pricing at \$12

Financial news for GNCA dated on 2014-02-05: Waiting on IPO Opens for:

Financial news for GNCA dated on 2014-02-05: Genocea Biosciences Announces Pricing of Initial Public Offering at \$12 per Share

Financial news for GNCA dated on 2013-12-23: Genocea Files Up to \$75M IPO